Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
McKesson ( (MCK) ) just unveiled an announcement.
On July 30, 2025, McKesson Corporation held its Annual Meeting of Shareholders, where several key decisions were made. The election of board members saw all nominated individuals successfully appointed, and Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending March 31, 2026. Additionally, the compensation of the company’s named executive officers was approved, reflecting shareholder support for the company’s leadership and strategic direction.
The most recent analyst rating on (MCK) stock is a Buy with a $579.00 price target. To see the full list of analyst forecasts on McKesson stock, see the MCK Stock Forecast page.
Spark’s Take on MCK Stock
According to Spark, TipRanks’ AI Analyst, MCK is a Outperform.
McKesson’s overall stock score is supported by strong financial performance and positive strategic initiatives, like acquisitions in oncology and biopharma services. However, technical indicators and high valuation metrics suggest caution. The balance sheet’s negative equity and regulatory uncertainties add to the risks, which are partially offset by robust earnings growth and cash flow generation.
To see Spark’s full report on MCK stock, click here.
More about McKesson
McKesson Corporation operates in the healthcare industry, providing pharmaceuticals, medical supplies, and healthcare management tools. The company focuses on improving healthcare services and efficiency through its extensive distribution network and technological solutions.
Average Trading Volume: 823,580
Technical Sentiment Signal: Buy
Current Market Cap: $86.63B
See more data about MCK stock on TipRanks’ Stock Analysis page.